Abstract:Amyloid beta (Aβ) plaques are pathological hallmarks of neurodegenerative Alzheimer's disease (AD) that is predominantly characterized by clinical symptoms of dementia. Therapies targeting Aβ are essential for preventing and treating AD. This review focuses on the non-amyloidogenic pathways that prevent the generation of Aβ peptide and thereby plaque formation in AD. An a-secretase-dependent cleavage of Amyloid Precursor Protein (APP) precludes the amyloidogenic pathway of Aβ generation. This non-amyloidogenic a-secretase activation thereby secretes sAPPa with prominent neurotrophic and memory-enhancing properties. Several "A Disintegrin and Metalloprotease" (ADAM) proteins, specifically ADAM17, ADAM10 and ADAM9, comprise active members of this a-secretase family. It is conventionally accepted that whereas ADAM10 executes constitutive APP cleavage, ADAM17 and ADAM9 are dedicated towards the regulated processing. Therefore, promoting a-secretase activity offers thorough neuroprotection against AD, and emerges as a pertinent strategy in attenuating Aβ. We discuss signaling pathways, particularly those mediated by protein kinase C and phorbol esters, that enhance ADAM functioning and sAPPa release. We also elaborate upon the associated M1 and M3-muscarinic acetylcholine receptors, ERK-MAP kinase, tyrosine kinase and calcium signaling pathways. Clinical studies suggest that regulated hormone and cholesterol levels are essential for restricting neurodegeneration, and here we illustrate the role of estrogen and testosterone and that of cholesterol-attenuating statins in generating sAPPa. We also emphasize the need for novel ADAM activators that may be screened for targeting the interleukin-1-responsive mRNA 5'-untranslated region of APP. This review offers an in-depth insight into pathways, strategies and probable therapies restricting AD pathology via its non-amyloidogenic route.

Proteolytic processing of Alzheimer's β-amyloid precursor protein.

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Functions of Amyloid Precursor Protein in Metabolic Diseases

Molecular and cellular mechanisms for Alzheimer's disease: understanding APP metabolism.

Secretases Related to Amyloid Precursor Protein Processing

Advances in the β-amyloid precursor protein of Alzheimer's disease

Regulation of β cleavage of amyloid precursor protein

Regulation Of Beta Cleavage Of Amyloid Precursor Protein

The amyloid precursor protein: beyond amyloid

Amyloid Precursor Protein Revisited

The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease.

Therapeutic Approaches to Alzheimer'S Disease Through Stimulating of Non-Amyloidogenic Processing of Amyloid Precursor Protein

Cellular and Molecular Basis of Beta-Amyloid Precursor Protein Metabolism

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Abeta-mediated neurotoxicity.

Biology and Pathophysiology of the Amyloid Precursor Protein

Physiological functions of APP family proteins.

The Release and Transmission of Amyloid Precursor Protein Via Exosomes

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

The Role of APP in Alzheimer’s Disease

Amyloid Precursor Protein Revisited: NEURON-SPECIFIC EXPRESSION AND HIGHLY STABLE NATURE OF SOLUBLE DERIVATIVES

Amyloid precursor protein-processing products affect mononuclear phagocyte activation: pathways for sAPP- and Aβ-mediated neurotoxicity: Microglia-mediated oxidative neurotoxicity